Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.
On February 12, 2026, Dr. Reddy’s Laboratories disclosed that its management will participate in an investor conference organized by Kotak Institutional Equities in Mumbai. The in-person group meeting with analysts and institutional investors is scheduled for February 23, 2026, between 09:00 and 17:00 IST, and may be rescheduled if required by either the investors or the company.
The planned engagement underscores Dr. Reddy’s ongoing outreach to the investment community across its Indian and U.S. listings. Regular participation in such conferences helps the company maintain transparency with stakeholders, potentially influencing investor sentiment and supporting its capital markets profile.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based pharmaceutical company engaged in the development, manufacture and marketing of generic medicines and active pharmaceutical ingredients for global markets. Listed in India and on the New York Stock Exchange, the company targets both domestic and international healthcare segments with a diversified portfolio of prescription and over-the-counter products.
Average Trading Volume: 1,447,076
Technical Sentiment Signal: Buy
Current Market Cap: $11.55B
See more data about RDY stock on TipRanks’ Stock Analysis page.